Can extra immunotherapy stall advanced lung cancer?

NCT ID NCT06219317

Ongoing Disease control Sponsor: European Organisation for Research and Treatment of Cancer - EORTC Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether continuing the immunotherapy drug cemiplimab for up to a year after initial treatment can delay cancer growth in people with stage IV non-small cell lung cancer that has spread to only a few places (oligometastatic). About 136 participants will be randomly assigned to receive either cemiplimab or a placebo. The study aims to see if the drug improves progression-free survival compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cemiplimab (an immunotherapy drug)
What this could lead to: If successful, this could show that continuing immunotherapy after initial treatment helps keep advanced lung cancer from growing for longer.
What could go wrong: This is a phase 2 trial with only 136 people, so results may not apply to everyone. Immunotherapy can cause immune-related side effects like inflammation in organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC STAGE IV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC STAGE IV

Contacts and locations

Locations

AUSL Della Romagna - Ospedale Santa Maria delle Croci

Ravenna, Italy
Academisch Ziekenhuis Maastricht

Maastricht, Netherlands
Azienda Ospedaliero - Universitaria "Santa Maria della Misericordia" di Udine

Udine, Italy
Azienda Unita Locale Socio-Sanitaria N. 9-Mater Salutis Hospital

Legnano, Italy
CH de La Cote Basque - Saint Leon

Bayonne, France
CHU Helora Pole Hospitalier Jolimont

Haine-Saint-Paul, Belgium
CHU Mont Godinne - UCL Namur

Yvoir, Belgium
Cliniques Universitaires Saint-Luc

Brussels, Belgium
Hospital De La Santa Creu I Sant Pau

Barcelona, Spain
Institut Paoli-Calmettes

Marseille, France
UOMi Cancer Center

Barcelona, Spain
University Hospital Virgen del Rocio

Seville, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.